nasdaq:dvax
|
590882
|
Apr 14th, 2024 12:00AM
|
Dynavax Technologies
|
14K
|
349.00
|
Open
|
|
Apr 13th, 2024 10:56PM
|
Apr 13th, 2024 10:56PM
|
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.
|
Open
|
Infectious Diseases, Biodefense, Vaccine Manufacturing and Vaccines
|
Open
|
2100 Powell St
|
Emeryville
|
CA
|
US
|
94608
|
|
Dynavax
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:dvax
|
590882
|
Apr 13th, 2024 12:00AM
|
Dynavax Technologies
|
14K
|
349.00
|
Open
|
|
Apr 12th, 2024 10:48PM
|
Apr 13th, 2024 11:22AM
|
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.
|
Open
|
Infectious Diseases, Biodefense, Vaccine Manufacturing and Vaccines
|
Open
|
2100 Powell St
|
Emeryville
|
CA
|
US
|
94608
|
|
Dynavax
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:dvax
|
590882
|
Apr 12th, 2024 12:00AM
|
Dynavax Technologies
|
14K
|
349.00
|
Open
|
|
Apr 11th, 2024 10:52PM
|
Apr 12th, 2024 08:17AM
|
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.
|
Open
|
Infectious Diseases, Biodefense, Vaccine Manufacturing and Vaccines
|
Open
|
2100 Powell St
|
Emeryville
|
CA
|
US
|
94608
|
|
Dynavax
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:dvax
|
590882
|
Apr 11th, 2024 12:00AM
|
Dynavax Technologies
|
14K
|
349.00
|
Open
|
|
Apr 10th, 2024 11:25PM
|
Apr 11th, 2024 11:02AM
|
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.
|
Open
|
Infectious Diseases, Biodefense, Vaccine Manufacturing and Vaccines
|
Open
|
2100 Powell St
|
Emeryville
|
CA
|
US
|
94608
|
|
Dynavax
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:dvax
|
590882
|
Apr 10th, 2024 12:00AM
|
Dynavax Technologies
|
14K
|
349.00
|
Open
|
|
Apr 9th, 2024 10:55PM
|
Apr 10th, 2024 05:10PM
|
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.
|
Open
|
Infectious Diseases, Biodefense, Vaccine Manufacturing and Vaccines
|
Open
|
2100 Powell St
|
Emeryville
|
CA
|
US
|
94608
|
|
Dynavax
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:dvax
|
590882
|
Apr 9th, 2024 12:00AM
|
Dynavax Technologies
|
14K
|
349.00
|
Open
|
|
Apr 8th, 2024 11:06PM
|
Apr 9th, 2024 09:52AM
|
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.
|
Open
|
Infectious Diseases, Biodefense, Vaccine Manufacturing and Vaccines
|
Open
|
2100 Powell St
|
Emeryville
|
CA
|
US
|
94608
|
|
Dynavax
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:dvax
|
590882
|
Apr 8th, 2024 12:00AM
|
Dynavax Technologies
|
14K
|
349.00
|
Open
|
|
Apr 7th, 2024 11:31PM
|
Apr 8th, 2024 06:50PM
|
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.
|
Open
|
Infectious Diseases, Biodefense, Vaccine Manufacturing and Vaccines
|
Open
|
2100 Powell St
|
Emeryville
|
CA
|
US
|
94608
|
|
Dynavax
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:dvax
|
590882
|
Apr 7th, 2024 12:00AM
|
Dynavax Technologies
|
14K
|
349.00
|
Open
|
|
Apr 6th, 2024 11:02PM
|
Apr 6th, 2024 11:02PM
|
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.
|
Open
|
Infectious Diseases, Biodefense, Vaccine Manufacturing and Vaccines
|
Open
|
2100 Powell St
|
Emeryville
|
CA
|
US
|
94608
|
|
Dynavax
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:dvax
|
590882
|
Apr 6th, 2024 12:00AM
|
Dynavax Technologies
|
14K
|
349.00
|
Open
|
|
Apr 5th, 2024 11:02PM
|
Apr 5th, 2024 11:02PM
|
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.
|
Open
|
Infectious Diseases, Biodefense, Vaccine Manufacturing and Vaccines
|
Open
|
2100 Powell St
|
Emeryville
|
CA
|
US
|
94608
|
|
Dynavax
|
|
Pharmaceuticals & Biotechnology
|
nasdaq:dvax
|
590882
|
Apr 5th, 2024 12:00AM
|
Dynavax Technologies
|
14K
|
349.00
|
Open
|
|
Apr 4th, 2024 11:29PM
|
Apr 4th, 2024 11:29PM
|
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, seasonal influenza, universal influenza, plague, shingles and Tdap. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn.
Dynavax is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, martial and veteran status.
|
Open
|
Infectious Diseases, Biodefense, Vaccine Manufacturing and Vaccines
|
Open
|
2100 Powell St
|
Emeryville
|
CA
|
US
|
94608
|
|
Dynavax
|
|
Pharmaceuticals & Biotechnology
|